TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29722847

Group type: EXPERIMENTAL
Intervention: High diet (high animal protein-to-potassium ratio)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Low diet (low animal protein-to-potassium ratio)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Typical in-flight intake at FD30
Number of subjects: 17

Group type: COMPARATOR
Intervention: Bed rest study control group (non-exercising subjects)
Number of subjects: 17
Study: 26561733

Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered cognitive behaviour therapy (ICBT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting list condition (WLC)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 46
Study: 24038489

Group type: EXPERIMENTAL
Intervention: Fexofenadine (transporter function)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CYP3A4 activity
Number of subjects: 18
Study: 22092492

Group type: EXPERIMENTAL
Intervention: Intervention School (IS) - 10 health-related lessons over 1 year, parents and teachers attended educational lessons and received newsletters.
Number of subjects: 724

Group type: COMPARATOR
Intervention: Control School (CS) - no specific intervention mentioned.
Number of subjects: 724
Study: 20019307

Group type: EXPERIMENTAL
Intervention: Calorie labels
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Calorie labels plus information
Number of subjects: 303

Group type: COMPARATOR
Intervention: No calorie labels
Number of subjects: 303
Study: 17890757

Group type: EXPERIMENTAL
Intervention: Intervention group (literacy assessments implemented with the Newest Vital Sign)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (no literacy assessments)
Number of subjects: 289
Study: 16435695

Group type: EXPERIMENTAL
Intervention: Isometric pushing exertions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pushing exertions
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Muscle cocontraction
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cocontraction
Number of subjects: 11
Study: 12850842

Group type: EXPERIMENTAL
Intervention: Roxifiban
Number of subjects: 0
Study: 10568679

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 (30-min intravenous infusion on days 1, 8, 15 of a 28-day cycle)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 (day 1) and etoposide 100 mg/m2 (days 1, 2, 3)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 147

Group type: COMPARATOR
Intervention: Cisplatin/etoposide
Number of subjects: 147
Study: 9092418

Group type: EXPERIMENTAL
Intervention: Platelet antiaggregants (aspirin and ticlopidine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulants (heparin, vitamin-K antagonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytics in the acute phase of myocardial infarction
Number of subjects: 0
Study: 1988398

Group type: EXPERIMENTAL
Intervention: Teaching, treadmill exercise testing, and exercise training (three times weekly for 5 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teaching and exercise testing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine care without supervised exercise or teaching
Number of subjects: 40
Study: 7049189

Group type: EXPERIMENTAL
Intervention: Clofibate (1.5 g daily for 10 days)
Number of subjects: 19
Study: 29286982

Group type: EXPERIMENTAL
Intervention: Zeno walkway
Number of subjects: 47

Group type: COMPARATOR
Intervention: GAITRite walkway
Number of subjects: 47
Study: 27747984

Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet (LFD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FOS supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 20
Study: 27439974

Group type: EXPERIMENTAL
Intervention: Educational intervention (16 hours of training including an introductory course and three workshops)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Guidance on leisure-time walking
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Guidance on healthy eating
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 24345317

Group type: EXPERIMENTAL
Intervention: Nepafenac (0.1%) eye drops, instilled 3 times a day
Number of subjects: 327

Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 327
Study: 22101095

Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG) - buffered gentamicin solution injected in the middle ear (maximum of 2 injections)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD) - 4 mg/mL, 3 injections at intervals of 1 every 3 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin (ITG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intratympanic dexamethasone (ITD)
Number of subjects: 60
Study: 19579617

Group type: EXPERIMENTAL
Intervention: Pringle maneuver (Group 1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Hemihepatic inflow control (Group 2)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Complete hemihepatic vascular occlusion with hanging maneuver (Group 3)
Number of subjects: 94
Study: 17456839

Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin (12 units)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subcutaneous insulin lispro (12 units)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: AIR inhaled insulin
Number of subjects: 45
Study: 15645892

Group type: EXPERIMENTAL
Intervention: Crest Whitestrips Supreme
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo strips
Number of subjects: 29
Study: 11714206

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension clinic
Number of subjects: 330

Group type: COMPARATOR
Intervention: Physician-managed clinic
Number of subjects: 330
Study: 9160847

Group type: EXPERIMENTAL
Intervention: Caffeine (average daily intake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 7949515

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral or intranasal formulations of pertussis vaccine
Number of subjects: 0
Study: 3586805

Group type: EXPERIMENTAL
Intervention: Autoinflation using a modified Valsalva technique with an anesthesia mask and flowmeter
Number of subjects: 35

Group type: COMPARATOR
Intervention: Traditional method using preinflation and postinflation tympanometry
Number of subjects: 35
Study: 31088557

Group type: EXPERIMENTAL
Intervention: Motivational interviewing in a fall prevention exercise program
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Regular meetings and follow-ups during treatment period
Number of subjects: 58
Study: 28422846

Group type: EXPERIMENTAL
Intervention: Remifentanil (80-2/3* age) combined with propofol (20-30 mg) for 1 to 2 minutes during ERCP and EST surgery
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sedative drugs not given
Number of subjects: 68
Study: 26040075

Group type: EXPERIMENTAL
Intervention: Low contextual interference
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Moderate contextual interference
Number of subjects: 57

Group type: COMPARATOR
Intervention: High contextual interference
Number of subjects: 57
Study: 25146074

Group type: EXPERIMENTAL
Intervention: MYCaW questionnaire
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Priority list of outcome areas
Number of subjects: 31
Study: 22963737

Group type: EXPERIMENTAL
Intervention: Healthy condition
Number of subjects: 352

Group type: COMPARATOR
Intervention: Diet condition
Number of subjects: 352

Group type: COMPARATOR
Intervention: Hedonic condition
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Normal-weight vs. Overweight/Obese
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Restraint status (unrestrained vs. restrained eaters)
Number of subjects: 352
Study: 19304716

Group type: EXPERIMENTAL
Intervention: Contrast medium dosage of 450 mg I/kg of estimated lean body weight (LBW)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Contrast medium dosage of 360 mg I/kg of total body weight (TBW)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Estimated LBW group
Number of subjects: 97

Group type: COMPARATOR
Intervention: TBW group
Number of subjects: 97
Study: 17510758

Group type: EXPERIMENTAL
Intervention: D-Cycloserine 50 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15388432

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g intravenously once daily for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g intravenously once daily for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both antibiotics
Number of subjects: 10
Study: 11820227

Group type: EXPERIMENTAL
Intervention: New nursing intervention to manage breathlessness
Number of subjects: 0
Study: 9806670

Group type: EXPERIMENTAL
Intervention: HES 130/0.4
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HES 200/0.5
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both HES solutions
Number of subjects: 80
Study: 7703045

Group type: EXPERIMENTAL
Intervention: Vancomycin (10 mg/kg i.v. every 6 hours, day‐5 to +1)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (without vancomycin)
Number of subjects: 155
Study: 2781421

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 33
Study: 1032878

Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 100
Study: 31076949

Group type: EXPERIMENTAL
Intervention: Dark Adaptation (DA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light Adaptation (Control)
Number of subjects: 0
Study: 28488142

Group type: EXPERIMENTAL
Intervention: Hydrating nail solution (HNS) applied once a day until grade 2 onycholysis, then twice a day thereafter.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 103
Study: 25238728

Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVR) using different endograft systems (Zenith, Excluder, AneuRx)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Open repair (control)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Endovascular repair (EVR) compared to open repair
Number of subjects: 881
Study: 24060673

Group type: EXPERIMENTAL
Intervention: Culturally-targeted, community-based lifestyle intervention consisting of 6 weeks of group classes followed by 12 weeks of individual telephone support.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving screening results and monthly mailings on CVD prevention.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally-targeted, community-based lifestyle intervention.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 0
Study: 21729342

Group type: EXPERIMENTAL
Intervention: Therapeutically induced change interventions
Number of subjects: 281
Study: 19701511

Group type: EXPERIMENTAL
Intervention: Peak LC Bond with self-etching technique on fluorotic enamel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Peak LC Bond with self-etching technique on nonfluorotic enamel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Peak LC Bond with etch-and-rinse technique on fluorotic enamel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Peak LC Bond with etch-and-rinse technique on nonfluorotic enamel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Xeno V one-bottle self-etching on fluorotic enamel
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Xeno V one-bottle self-etching on nonfluorotic enamel
Number of subjects: 72
Study: 16822276

Group type: EXPERIMENTAL
Intervention: Lasofoxifene (0.25 mg) with ketoconazole (400 mg daily x 20 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lasofoxifene (0.25 mg) with fluconazole (400 mg daily x 20 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lasofoxifene (0.25 mg) with paroxetine (30 mg qd x 21 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lasofoxifene (0.25 mg) alone
Number of subjects: 65
Study: 15193896

Group type: EXPERIMENTAL
Intervention: Thorough skin self-examination (TSSE)
Number of subjects: 2126

Group type: EXPERIMENTAL
Intervention: Using a partner to assist in TSSE
Number of subjects: 2126

Group type: EXPERIMENTAL
Intervention: Availability of a wall mirror
Number of subjects: 2126

Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 2126
Study: 11434709

Group type: EXPERIMENTAL
Intervention: Free TFPI (f‐TFPI)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Total TFPI (t‐TFPI)
Number of subjects: 626
Study: 9595996

Group type: EXPERIMENTAL
Intervention: Neurogenic thoracic outlet syndrome
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sternotomy-related brachial plexopathy
Number of subjects: 24
Study: 8044386

Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EPO 300 U/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: EPO 600 U/kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2223168

Group type: EXPERIMENTAL
Intervention: Group instruction
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Individual instruction
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Individual instruction with a reminder system
Number of subjects: 783

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 783
Study: 798709

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxprenolol-Isosorbide dinitrate (combination)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oxprenolol-Nifedipine (combination)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30782014

Group type: EXPERIMENTAL
Intervention: Caregiver-guided pain coping skills training intervention
Number of subjects: 214

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual (Control)
Number of subjects: 214
Study: 28777983

Group type: EXPERIMENTAL
Intervention: Vitamin D3 5000 IU po qday for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25767183

Group type: EXPERIMENTAL
Intervention: HydroCoil
Number of subjects: 288

Group type: COMPARATOR
Intervention: bare-platinum coils
Number of subjects: 288
Study: 23237137

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 1339

Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (E-ZES)
Number of subjects: 1339
Study: 16823652

Group type: EXPERIMENTAL
Intervention: Haptic feedback training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonhaptic training
Number of subjects: 38
Study: 12598993

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 20 mg of butylscopolamine 10 min before MR examination
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received only an oral solution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 10578460

Group type: EXPERIMENTAL
Intervention: Right prefrontal rTMS
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 35
Study: 8914876

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day + Enalapril 10 mg twice a day (group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard-dose Enalapril 10 mg twice a day (group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-dose Enalapril 20 mg twice a day (group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Losartan + Enalapril
Number of subjects: 120
Study: 1802209

Group type: EXPERIMENTAL
Intervention: Strict nutritional protocol covering needs and satisfying tastes and habits
Number of subjects: 93

Group type: COMPARATOR
Intervention: Ad libitum diet
Number of subjects: 93
Study: 6407278

Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31744521

Group type: EXPERIMENTAL
Intervention: Bang® Pre-Workout Master Blaster® (BMB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study: 28479178

Group type: EXPERIMENTAL
Intervention: BCG needle and syringe (BCG NS)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Device A
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Device B
Number of subjects: 452
Study: 26385034

Group type: EXPERIMENTAL
Intervention: Early beta-blocker therapy
Number of subjects: 14241

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 14241
Study: 23249415

Group type: EXPERIMENTAL
Intervention: Eminol® (grape extract) 700 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21724659

Group type: EXPERIMENTAL
Intervention: Nitinol mesh-supported graft
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional vein grafts
Number of subjects: 25

Group type: COMPARATOR
Intervention: Arterial grafts
Number of subjects: 25
Study: 19502264

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg body weight at 0, 2, 6 weeks and then q 8 weeks for a total of 24 weeks, total of five doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (conventional treatment only)
Number of subjects: 27
Study: 17052498

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle preirradiation and postirradiation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 14519613

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for depression and parenting skills enhancement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mothers' support group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 11012497

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% - Lidocaine 1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.375% - Lidocaine 1%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (Ropivacaine 0.5%)
Number of subjects: 90
Study: 8774276

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy followed by IM injection of 5,000 IU hCG
Number of subjects: 64
Study: 1727843

Group type: EXPERIMENTAL
Intervention: Red light therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Infrared light therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6091474

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of ceftriaxone
Number of subjects: 81

Group type: COMPARATOR
Intervention: Multidose cefazolin (one preoperative and three postoperative doses)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Multidose cefazolin
Number of subjects: 81
Study: 31561727

Group type: EXPERIMENTAL
Intervention: Mobile-Bearing Total Ankle Replacement (MB-TAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed-Bearing Total Ankle Replacement (FB-TAR)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MB-TAR
Number of subjects: 100

Group type: COMPARATOR
Intervention: FB-TAR
Number of subjects: 100
Study: 29209814

Group type: EXPERIMENTAL
Intervention: Teleconsultation (web-based care)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 74

Group type: COMPARATOR
Intervention: Telemedicine group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 74
Study: 26479973

Group type: EXPERIMENTAL
Intervention: 3-dose MenACWY-CRM vaccination series
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: 4-dose MenACWY-CRM vaccination series
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: 3-dose MenACWY-CRM with PCV13
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: 4-dose MenACWY-CRM with PCV13
Number of subjects: 751

Group type: COMPARATOR
Intervention: Routine vaccinations only
Number of subjects: 751
Study: 25269467

Group type: EXPERIMENTAL
Intervention: Dental implants placed through skin flaps
Number of subjects: 75

Group type: COMPARATOR
Intervention: Dental implants placed through oral mucosa
Number of subjects: 75
Study: 23096987

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix‐assisted, tissue expander/implant reconstruction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Submuscular tissue expander/implant placement
Number of subjects: 70
Study: 20594055

Group type: EXPERIMENTAL
Intervention: High-concentration eucalyptus extract (0.6%)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Low-concentration eucalyptus extract (0.4%)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 17331985

Group type: EXPERIMENTAL
Intervention: Intraduodenal lauric acid (C12) at different loads (0.2, 0.3, 0.4 kcal min(‐1) for 90 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intraduodenal lauric acid (C12) at different concentrations (40, 56, 72 mM at 0.4 kcal min(‐1) for 60 min)
Number of subjects: 24
Study: 16260974

Group type: EXPERIMENTAL
Intervention: MLSSsingle
Number of subjects: 8
Study: 12243599

Group type: EXPERIMENTAL
Intervention: 5 mL/kg/d of amniotic fluid solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mL/kg/d of amniotic fluid solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mL/kg/d of amniotic fluid solution
Number of subjects: 30
Study: 10195535

Group type: EXPERIMENTAL
Intervention: 4 Hz
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 15/30 Hz
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 100 Hz
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham-PENS (0 Hz)
Number of subjects: 68
Study: 8562004

Group type: COMPARATOR
Intervention: AIDS prevention program led by teachers, developed with local AIDS experts, social scientists, and health educators; aimed to provide accurate information about AIDS, foster positive attitudes, and develop skills for assessing intended behavior.
Number of subjects: 804